Andrew J.  Armanino net worth and biography

Andrew Armanino Biography and Net Worth

Director of Better Therapeutics
Andy Armanino has served as a member of Better’s board of directors since March 2021. Mr. Armanino is currently the chairman of the board of directors of Moore Global International, an accounting and business advisory network of independent accounting firms. He is also a member of the board of directors of Armanino Foundation, a community service organization and serves on the American Institute of CPAs council, and a member of the board of directors of the California Bank of Commerce. Mr. Armanino was the Managing Partner and Chief Executive Officer of Armanino LLP, a 1,500-person public accounting firm, from 2005 to 2018, at which time he retired and is no longer affiliated with the firm. He has a B.S. in accounting from Santa Clara University. We believe Mr. Armanino is well equipped to be a director of Better due to the depth and breadth of his business, accounting, and management experience. Mr. Armanino’s significant accounting experience provides in-depth knowledge of generally accepted accounting principles and auditing standards to the Board. With years of providing services to small and medium-sized businesses, he brings valuable insights to the Board regarding these businesses, which are similar to the Bank’s business customers.

What is Andrew J. Armanino's net worth?

The estimated net worth of Andrew J. Armanino is at least $0.00 as of July 27th, 2023. Mr. Armanino owns 728,368 shares of Better Therapeutics stock worth more than $0 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Armanino may own. Learn More about Andrew J. Armanino's net worth.

How do I contact Andrew J. Armanino?

The corporate mailing address for Mr. Armanino and other Better Therapeutics executives is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. Better Therapeutics can also be reached via phone at 415-887-2311 and via email at [email protected]. Learn More on Andrew J. Armanino's contact information.

Has Andrew J. Armanino been buying or selling shares of Better Therapeutics?

Andrew J. Armanino has not been actively trading shares of Better Therapeutics in the last ninety days. Most recently, on Thursday, July 27th, Andrew J. Armanino bought 274,010 shares of Better Therapeutics stock. The stock was acquired at an average cost of $0.73 per share, with a total value of $200,027.30. Following the completion of the transaction, the director now directly owns 728,368 shares of the company's stock, valued at $531,708.64. Learn More on Andrew J. Armanino's trading history.

Who are Better Therapeutics' active insiders?

Better Therapeutics' insider roster includes Kevin Appelbaum (CEO), Andrew Armanino (Director), Elder Granger (Director), Mark Heinen (Insider), and Risa Lavizzo-Mourey (Director). Learn More on Better Therapeutics' active insiders.

Andrew J. Armanino Insider Trading History at Better Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2023Buy274,010$0.73$200,027.30728,368View SEC Filing Icon  
3/29/2022Buy40,000$2.14$85,600.00View SEC Filing Icon  
12/13/2021Buy21,000$5.48$115,080.00View SEC Filing Icon  
11/29/2021Buy17,000$6.96$118,320.00View SEC Filing Icon  
See Full Table

Andrew J. Armanino Buying and Selling Activity at Better Therapeutics

This chart shows Andrew J Armanino's buying and selling at Better Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Better Therapeutics Company Overview

Better Therapeutics logo
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

2,000 shs

Average Volume

2,449,991 shs

Market Capitalization

$5,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89